Myeloma Canada | Research & Access Updates

— Tuesday, November 19 2019

Approval of Daratumumab in Combination with Lenalidomide and Dexamethasone for Newly Diagnosed Patients Who Are Transplant Ineligible

The Janssen Pharmaceutical Companies of Johnson & Johnson announced that Health Canada recently approved ...

— Thursday, October 24 2019

We are seeing some very promising results with Chimeric antigen receptor (CAR) T-cell therapy in early ph...

— Monday, October 21 2019

The Canadian Agency for Drugs and Technologies in Health recommanded the reimbursement for Pomalidomide (...

— Friday, October 11 2019

On October 4th and 5th, leading hematologists and myeloma researchers from around the country and the Uni...

— Friday, October 4 2019

As of Aug 16, 2019, Darzalex has been approved in Newfoundland, in combination with Lenalidomide and Dexa...

— Friday, July 26 2019

As of July 15, Darzalex (daratumumab) has been approved in Saskatchewan, in combination with lenalidomide...